Simulating Alpha Particle Doses at the Micron Scale from Prostate Cancer Patient Derived Bone Metastatic Biopsies Using GATE

Abstract

Radiopharmaceutical therapies are poised to enhance patient care for several currently untreatable metastatic cancers. Radium-223 dichloride citrate is indicated for treatment of bone metastatic castrate resistant prostate cancer, serving as the primary use of alpha particle emitting radium to irradiate bone lesions. Improvements and refinement of such therapies relies on patient centric and micro scale quantification to assess and compare efficacy. Computational modeling and Monte Carlo simulations provide a valuable tool for understanding micro scale phenomena of radiopharmaceutical therapies. Via simulation, we undertake and illuminate dose profiles of radium-223 dichloride treatment, evaluating energy and dose distributions based on primary, patient-derived specimens. A set of four activity distributions were simulated on three patient bone lesion biopsy samples. These simulations validate the novel tool for micron-scale modeling with patient-derived specimens. Ablative dose profiles are shown to be driven by uptake distributions as well as the target tissues microstructure.